title: Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates.
abstract: OBJECTIVE
  The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment.
  
  
  METHODS
  Retrospective study of neonates with thrombosis treated between January 2008 and December 2014.
  
  
  RESULTS
  Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg(-1), respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml(-1)) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state.
  
  
  CONCLUSIONS
  Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.
authors.affiliation: Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Goldsmith
authors.affiliation: Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Chan
authors.affiliation: Division of Neonatology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
authors.forename: B A
authors.initials: BA
authors.lastname: Paes
authors.affiliation: Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
authors.forename: M D
authors.initials: MD
authors.lastname: Bhatt
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D047928:Premature Birth; D012189:Retrospective Studies; D047929:Term Birth; D013927:Thrombosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin